Emergent BioSolutions Inc.
EBSNYSE
$7.63
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↑ +9.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$431.1M
Enterprise Value
$844.4M
P/E
—
P/S
0.6
P/B
0.8
EV/EBITDA
5.5
PEG
—
FCF Yield
31.4%
Dividend Yield
—
Revenue (TTM)
$676.8M
Net Income (TTM)
-$8.6M
Free Cash Flow (TTM)
$135.4M
Gross Margin
—
Operating Margin
9.0%
Net Margin
-1.3%
ROE
-1.6%
ROIC
3.2%
Debt / Equity
1.1
Net Cash
-$413.3M
Return 1Y
+4.8%
Company profile
Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.
- CEO
- Robert G. Kramer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2,420
- Headquarters
- Maryland
- Website
- emergentbiosolutions.com
Management & directors
- Williams Paul AnthonySVP, Products Business
- Glessner ColeenEVP, Quality & Ethics, and CPL
- Hartzel WilliamSVP, Bioservices
- Lindahl Richard SEVP, Chief Financial Officer
- Harsanyi ZsoltChairman
- Lowry Simon CSVP, R&D, CMO
- Papa Joseph CPresident and CEO
- Perl JessicaSVP, General Counsel, Corp Sec
Roles derived from SEC Form 4 filings.
Earnings
EBS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$156.1M↓ -29.7%
Diluted EPS$0.07↓ -94.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.8B | $1.1B | $1.0B | $1.0B | $742.9M |
| Gross profit | $925.2M | $891.3M | $383.0M | $317.6M | — | — |
| Operating income | $438.5M | $341.4M | -$170.0M | -$726.4M | -$108.7M | $100.1M |
| Net income | $305.8M | $219.5M | -$211.6M | -$760.5M | -$190.6M | $52.6M |
| Diluted EPS | $5.68 | $4.06 | -$4.22 | -$14.85 | -$3.60 | $0.93 |
| Operating cash flow | $536.9M | $320.2M | -$34.1M | -$206.3M | $58.7M | $170.6M |
| Free cash flow | $395.0M | $96.1M | -$149.9M | -$257.9M | $35.8M | $156.8M |
| Gross margin | 58.7% | 50.3% | 34.3% | 30.3% | — | — |
| Operating margin | 27.8% | 19.2% | -15.2% | -69.2% | -10.4% | 13.5% |
| Net margin | 19.4% | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $254.7M | $293.8M | $194.7M | $222.2M | $140.9M | $231.1M | $148.7M | $156.1M |
| Gross profit | -$48.0M | $161.2M | — | — | — | — | — | — |
| Operating income | -$203.5M | $64.5M | -$9.5M | $49.9M | $1.6M | $76.5M | -$27.9M | $10.5M |
| Net income | -$283.1M | $114.8M | -$31.3M | $68.0M | -$12.0M | $51.2M | -$54.6M | $6.8M |
| Diluted EPS | -$5.38 | $2.06 | -$0.45 | $1.19 | -$0.22 | $0.91 | -$0.95 | $0.07 |
| Operating cash flow | $47.5M | $153.7M | -$79.9M | -$11.2M | $106.4M | -$2.3M | $77.7M | -$33.8M |
| Free cash flow | $42.9M | $147.9M | -$81.6M | -$14.8M | $103.5M | -$5.7M | $73.8M | -$36.2M |
| Gross margin | -18.8% | 54.9% | — | — | — | — | — | — |
| Operating margin | -79.9% | 22.0% | -4.9% | 22.5% | 1.1% | 33.1% | -18.8% | 6.7% |
| Net margin | -111.2% | 39.1% | -16.1% | 30.6% | -8.5% | 22.2% | -36.7% | 4.4% |
Company news
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Williams Paul Anthony· SVP, Products Business | Sale | 3,000 | $8.40 | $25,200.00 | filing |
| 2026-06-08 | LINDAHL RICHARD S· EVP, Chief Financial Officer | Tax withholding | 3,964 | $8.00 | $31,712.00 | filing |
| 2026-06-08 | Glessner Coleen· EVP, Quality & Ethics, and CPL | Tax withholding | 2,018 | $8.00 | $16,144.00 | filing |
| 2026-06-08 | Hartzel William· SVP, Bioservices | Tax withholding | 1,741 | $8.00 | $13,928.00 | filing |
| 2026-06-08 | Williams Paul Anthony· SVP, Products Business | Tax withholding | 694 | $8.00 | $5,552.00 | filing |
| 2026-05-01 | Zoon Kathryn C | Sale | 16,145 | $8.36 | $134,972.20 | filing |
| 2026-05-01 | DeGolyer Donald W | Sale | 14,527 | $8.36 | $121,445.72 | filing |
| 2026-05-01 | Dayal Sujata Tyagi | Sale | 12,781 | $8.36 | $106,849.16 | filing |
| 2026-05-01 | Zoon Kathryn C | Sale | 1,057 | $8.97 | $9,481.29 | filing |
| 2026-05-01 | Dayal Sujata Tyagi | Sale | 980 | $8.94 | $8,761.20 | filing |
| 2026-05-01 | DeGolyer Donald W | Sale | 954 | $8.96 | $8,547.84 | filing |
| 2026-04-30 | Katkin Keith | Sale | 15,481 | $8.28 | $128,182.68 | filing |
| 2026-04-30 | DeGolyer Donald W | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Katkin Keith | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Dayal Sujata Tyagi | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | White Marvin L | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | FOWLER JOHN D JR | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Richard Ronald | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Zoon Kathryn C | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Fowler Neal Franklin | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-30 | Harsanyi Zsolt· Chairman | Award | 25,344 | $0.00 | $0.00 | filing |
| 2026-04-29 | Williams Paul Anthony· SVP, Products Business | Award | 100,111 | $0.00 | $0.00 | filing |
| 2026-04-29 | Lowry Simon C· SVP, R&D, CMO | Award | 100,111 | $0.00 | $0.00 | filing |
| 2026-04-29 | Glessner Coleen· EVP, Quality & Ethics, and CPL | Award | 100,111 | $0.00 | $0.00 | filing |
| 2026-04-29 | LINDAHL RICHARD S· EVP, Chief Financial Officer | Award | 162,680 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.